Dublin, Feb. 20, 2025 (GLOBE NEWSWIRE) -- The "Downstream Processing - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Downstream ...

Dublin, Feb. 21, 2024 (GLOBE NEWSWIRE) -- The "Downstream Processing Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering. The ...

Over two-thirds of biopharmaceutical manufacturers now report that their facility is experiencing capacity bottlenecks due to downstream processing. A number of factors continue to converge to create ...

Biomanufacturing is different from other processing industries. It is less able to sustain continuous end-to-end flows because it must contend with unique technical, practical, regulatory, and ...

Downstream processing can be the cause of a bottleneck in manufacturing, particularly for complex biologics, leading to a ...

With multiple, complex chromatographic purification, buffer exchange, and viral inactivation steps, downstream processing of monoclonal antibodies (mAbs) remains the major bottleneck in ...

With the recent FDA approval of the CAR T-cell therapies Kymriah ® from Novartis and Yescarta ® from Kite Pharma, there has been a renewed interest in bioprocessing and the manufacturing facilities ...

Drug development and manufacturing have undergone a seismic shift in the last two decades, 1 from blockbuster small molecules to highly personalized biologics 2 and cell and gene therapies. Because ...

Downstream processing encompasses the suite of separation, purification and formulation steps required to convert fermentation broths or other bioreactor outputs into high-purity bio-based chemicals.

Surveys show downstream processing remains a serious bottleneck – one that significantly impacts overall production. 3 Surging demand for treatments and vaccines fueled by the COVID-19 pandemic has ...